IMVT (Immunovant) Degree of Operating Leverage : 0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IMVT Immunovant Inc IMVT
29 GF Score
Price $43.35
! 3 Warning Signs
View Full Analysis

What is Immunovant Degree of Operating Leverage?

Immunovant IMVT -2.37% 29 Degree of Operating Leverage is 0.00 as of Jun. 2026. GuruFocus rates IMVT with a GF Score™ of 29/100. The stock has 3 warning signs investors should review. Among 854 Biotechnology companies, Immunovant ranks worse than 117095.9% on this metric.

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Immunovant does not have enough data to calculate Degree of Operating Leverage.


Immunovant  (NAS:IMVT) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Immunovant Degree of Operating Leverage Related Terms


Immunovant Degree of Operating Leverage Historical Data

* Premium members only.

The historical data trend for Immunovant's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunovant Degree of Operating Leverage Chart

Immunovant Annual Data
Trend Dec18 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Degree of Operating Leverage
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Immunovant Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

IMVT vs PCVX, TGTX, PTGX: Degree of Operating Leverage Comparison

For the Biotechnology subindustry, Immunovant's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunovant Degree of Operating Leverage vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunovant's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Immunovant's Degree of Operating Leverage falls into.


IMVT
29GF Score
Immunovant Inc IMVT
Degree of Operating Leverage is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immunovant Degree of Operating Leverage Calculation

Immunovant's Degree of Operating Leverage for the quarter that ended in Jun. 2026 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -566.001 (Jun. 2026) / -471.094 (Jun. 2025) - 1 )/( 0 (Jun. 2026) / 0 (Jun. 2025) - 1 )
=0.2015/
=N/A***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.

What does a Degree of Operating Leverage of 0.00 mean?
Immunovant (IMVT) has a Degree of Operating Leverage of 0.00 as of Jun. 2026. Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. View historical data for Immunovant and its competitors. According to the industry distribution chart, Immunovant ranks #999999 out of 854 companies in the Biotechnology industry.
Is Immunovant's Degree of Operating Leverage too high?
Immunovant's current Degree of Operating Leverage is 0.00. Based on the distribution chart, Immunovant ranks #999999 out of 854 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Immunovant has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Immunovant's Degree of Operating Leverage compare to PCVX and TGTX?
According to the Biotechnology industry distribution chart, Immunovant ranks #999999 out of 854 companies for Degree of Operating Leverage. This places Immunovant in the lower half of its industry. The industry median Degree of Operating Leverage is 0.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Degree of Operating Leverage for a Biotechnology company?
The median Degree of Operating Leverage among Biotechnology companies is 0.01, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Degree of Operating Leverage significantly above this median, while those in the bottom quartile fall well below. However, Degree of Operating Leverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Degree of Operating Leverage mean?
A high Degree of Operating Leverage can signal that a stock is expensive relative to its fundamentals. Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. View historical data for Immunovant and its competitors. For the Biotechnology industry, the median Degree of Operating Leverage is 0.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immunovant's current Degree of Operating Leverage is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunovant stock overvalued right now?
Immunovant (IMVT) has a current Degree of Operating Leverage of 0.00. The current Degree of Operating Leverage is 0.00. Immunovant's overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Degree of Operating Leverage calculated?
Degree of Operating Leverage is calculated from a company's financial statements. For Immunovant (IMVT), the current Degree of Operating Leverage is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Immunovant Business Description

Address 1000 Park Forty Plaza, New York, NC, USA, 27713
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
29GF Score

Get the complete analysis for IMVT

Degree of Operating Leverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$43.35
Price